Caris Life Sciences, a United States-based molecular science company, announced on Tuesday that it has named Matthew Oberley, MD, PhD, as its new executive medical director.
Dr Oberley joined the company in August 2019 as senior medical director and has functioned as a leading face for Caris' clinical and scientific expertise in the marketplace and research community. Prior to joining Caris, Dr Oberley held roles at the University of Southern California and, most recently, Children's Hospital Los Angeles.
His responsibilities have included managing the company's Medical Science Liaison team and helping connect key oncology research leaders across the country with the large datasets Caris has generated through the Company's molecular profiling technology. In his expanded role, Dr Oberley will manage the company's quality and fidelity of the medical operations facilities to ensure patient safety. Dr Oberley will lead Caris' pathology and genetics teams.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA